share_log

JMP Securities Reiterates Market Outperform on Sutro Biopharma, Maintains $17 Price Target

Benzinga ·  Dec 12 01:32  · Ratings

JMP Securities analyst Reni Benjamin reiterates Sutro Biopharma (NASDAQ:STRO) with a Market Outperform and maintains $17 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment